December 27, 2024
| Trial | TAK-676-1002 |
|---|---|
| Cancer Type | Miscellaneous and Non-specific |
| Hospital(s) | Belfast City Hospital |
| Information | An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors. |